2Dredge K, Horsfall R. Robinson SP. et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc Res, 2005, 69(1-2):56-63.
3Geitz H, Handt S. Zwingenberger K,et al. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 1996, 31(2 3):213-221
4Gupta D. Treon SP. Hidehima T, et al. Adherence of muhiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion:therapeutic applications.Leukemia, 2001, 15(12)41950-1961.
5Richardson P. Schlossman R. Anderson K. al,Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed muhiple myeloma, Blood.2002, 100(9):3063-3067.
6Nicholas M, Constantine S, Mitsiades, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99(12):4525-4530.
7Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in muhiple myeloma(MM) cells. J Biol Chem, 2003, 278(20):17593-17596.
8Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicityin multiple myeloma. Blood, 2001, 98(1):210-216.
9Martin J, Andrea P, Ann-Marl F, et al. Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion. Blood, 9005, 106:960a.
10Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000. 96(9) :2943-2950.
二级参考文献1
1O. Sezer,K. Niem?ller,J. Eucker,C. Jakob,O. Kaufmann,I. Zavrski,M. Dietel,K. Possinger. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma[J] 2000,Annals of Hematology(10):574～577
7Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adeno carcinoma of the ovary[J]. Gynecol Oncol, 1993, 50(3):347-351.
8Bloss JD, Brady MK, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase Ⅱ trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma: a Gynecologic Oneology Group Study[J]. Gynecol Oneol, 2003, 89(1): 148-154.
9Vasey PA, Jayson GC, Gordon A, et al. Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma [J]. J Natl Cancer Inst, 2004, 96(22):1682.
10Escobar PF, Markman M, Rose P, et al. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers[J]. Gynecol Oncol, 2004, 92(1):192-196.
